Topics:
Gastrointestinal Cancers • Medical Oncology
Would you consider trastuzumab deruxtecan for a patient with metastatic HER2+ colorectal cancer even if the cancer is RAS mutated?
Would you extrapolate from the DESTINY-CRC01 study, even though RAS/RAF mutations were excluded?
Answer from: Medical Oncologist at Academic Institution
The best available evidence for the role of trastuzumab deruxtecan (T-DXd) in HER2 positive (IHC 3+ or IHC2+/FISH+) colorectal cancer is the DESTINY-CRC01 study (cohort A) which showed a response rate of 45.3%, median progression-free survival of 4.1 months in patients who had >=2 lines of treatm...
Sign in or Register to read more